Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Centogene Enters Clinical Whole-Genome Sequencing Market for Rare Disease Diagnostics

Centogene Enters Clinical Whole-Genome Sequencing Market for Rare Disease Diagnostics

Dec 08, 2016
|
Julia Karow
Premium

NEW YORK (GenomeWeb) – German genetic diagnostics firm Centogene is betting on whole-genome sequencing for improving the interpretation of genetic variants in patients with rare genetic disorders.

Last week, the company said it installed Illumina's HiSeq X sequencing platform at its clinical laboratory in Rostock in the Northeast of Germany in order to provide diagnostic whole-genome sequencing services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

European Regulators Begin Review of Sputnik V

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Irish Funding Agency Seeks Boost

Science reports that Science Foundation Ireland is seeking annual budget increases.

Lower Fees Sought

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

Nature Papers Examine Peregrine Falcon Migration Patterns, Tool to Search Single-Cell Data

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Molecular Diagnostics

  1. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

  2. C2i Genomics Acquires Sequencing Lab QNA Dx

  3. Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

  4. Qiagen MDx Sample Processing Platform Garners CE-IVD Mark

  5. Genetic Technologies Inks US Commercialization Deal for COVID-19 Risk Test With Infinity Biologix

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.